Vaupel P, Menke H
Department of Applied Physiology, University of Mainz, F.R.G.
Adv Exp Med Biol. 1987;215:393-8. doi: 10.1007/978-1-4684-7433-6_48.
Tumour blood flow, an important determinant of the efficacy of presently available nonsurgical cancer treatments, significantly increased following a single I.V. injection of the calcium antagonist flunarizine. At a dose of 1 mg/kg, tumour blood flow increased approximately by 28% without a significant change in mean arterial blood pressure. The flow increase was paralleled by a similar improvement of the O2 availability to the cancer cells. The data suggest that flunarizine may provide a means of improving delivery of antineoplastic agents to tumours. Furthermore, flunarizine may also enhance the effectiveness of irradiation by increasing tumour oxygenation.
肿瘤血流是目前可用的非手术癌症治疗疗效的一个重要决定因素，在静脉单次注射钙拮抗剂氟桂利嗪后显著增加。在剂量为1毫克/千克时，肿瘤血流增加了约28%，而平均动脉血压没有显著变化。血流增加的同时，癌细胞的氧供应也有类似改善。数据表明，氟桂利嗪可能提供一种改善抗肿瘤药物向肿瘤输送的方法。此外，氟桂利嗪还可能通过增加肿瘤氧合来提高放疗效果。
